CAJ | 학술논문

目的：观察呲柔比星（ THP）膀胱内灌注在膀胱癌术后治疗中的效果，为临床治疗提供参考依据。方法：选择85例我院诊治的膀胱移行上皮细胞癌术后患者作为研究对象，根据患者是否接受THP灌注分为灌注组和非灌注组，非灌注组不进行灌注，灌注组用THP 30 mg进行膀胱灌注，每周1次，共8次，后改为每月1次，共8次，总疗程10个月，进行随访并对其疗效进行评价。结果：灌注组1年复发率为11．3％，2年复发率为20．8％，非灌注组1年复发率为46．9％，2年复发率为65．6％，差异有统计学意义（ P ＜0．05）。两组患者经过10个月的治疗后，均有尿频、尿急、尿痛等不良反应症状出现者，组间差异无统计学意义（P＞0．05）。结论：膀胱癌术后进行呲柔比星膀胱灌注可以明显降低术后复发率。
목적：관찰자유비성（ THP）방광내관주재방광암술후치료중적효과，위림상치료제공삼고의거。방법：선택85례아원진치적방광이행상피세포암술후환자작위연구대상，근거환자시부접수THP관주분위관주조화비관주조，비관주조불진행관주，관주조용THP 30 mg진행방광관주，매주1차，공8차，후개위매월1차，공8차，총료정10개월，진행수방병대기료효진행평개。결과：관주조1년복발솔위11．3％，2년복발솔위20．8％，비관주조1년복발솔위46．9％，2년복발솔위65．6％，차이유통계학의의（ P ＜0．05）。량조환자경과10개월적치료후，균유뇨빈、뇨급、뇨통등불량반응증상출현자，조간차이무통계학의의（P＞0．05）。결론：방광암술후진행자유비성방광관주가이명현강저술후복발솔。
Objective:To study the effect of pirarubicin ( THP) through intravesical perfusion after the surgery of bladder cancer and provide reference for clinical treatment .Method:85 transitional cell carcino-ma of bladder patients treated with surgery in our hospital were selected as research subjects.According to the patients accepted perfusion or not, They were divided into two groups.Patients in non-perfusion group were not underwent perfusion .Intravesical instillation of 30 mg of THP was given to patients in perfusion group once a week for 8 weeks, then subsequently once a month for 8 months.The patients were followed up and the treatment efficiency was evaluated .Result:1 year recurrence rate in perfusion group was 11 .3%, 2-year recurrence rate was 20.8%, 1-year recurrence rate in non-perfusion group was 46.9%, 2-year re-currence rate was 65.6%, the difference was statistically significant (P <0.05).After 10 months of treat-ment, the two groups of patients were adverse reactions of urinary frequency, urgency, dysuria and other symptoms of bladder irritation.There's statistically significant difference between the groups (P>0.05). Conclusion:Pirarubicin through intravesical perfusion after the surgery of bladder cancer can obviously re-duce postoperative recurrence rate.